Navigation Links
First Alzheimer’s Disease Gene Therapy Human Study Provided by Maximum Life Foundation, Offers 10 Free Therapies for Qualifying Patients
Date:12/30/2019

Cure Now ? Instead of Palliative Care

According to the Alzheimer’s Association:

  •     Alzheimer's disease is the 6th leading cause of death in the United States.
  •     More than 16 million Americans provide unpaid care for people with Alzheimer's or other dementia.
  •     These caregivers provided an estimated 18.5 billion hours of care valued at nearly $234 billion.
  •     Between 2000 and 2017 deaths from heart disease have decreased 9% while deaths from Alzheimer's have increased 145%.
  •     1 in 3 seniors dies with Alzheimer's or another dementia. It kills more than breast cancer and prostate cancer combined.

Alzheimer's costs Americans $277 billion a year – and rising. Sharp increases in Alzheimer's disease cases, deaths and costs are stressing the U.S. healthcare system and caregivers. About 5.7 million Americans have Alzheimer's disease. To date, no one has survived it.

Improvements of AD symptoms and the recovery of normal brain functions have been demonstrated in-vivo in mouse experiments, and in-vitro in human cell experiments through the rejuvenation of microglia (the brain’s first line of defense against infection) and neurons as well as stimulating mitochondrial function using the telomerase reverse transcriptase (TERT) protein.

One human patient received a lower dose therapy in August 2018 with no adverse side effects. To date, the patient’s disease has not progressed. MaxLife hopes to see symptom reversals in the next patients.

“If we can prove a benefit to patients that have no other option now, we can potentially treat Alzheimer’s Disease in people in early to mid-stage Alzheimer’s, finally creating effective medicine at the cellular level,” states Kekich. “If successful, this treatment could potentially be used on other diseases such as Parkinson’s and ALS.”

The unique difference is developing treatments against the cellular degeneration caused by aging as the root cause of most major diseases. Studies have proven aging is the leading risk factor for many life-threatening diseases, including Alzheimer's.

With a world class Scientific Advisory Board, MaxLife is ready to push forward into practical solutions. A gene therapy facilitator, Integrated Health Systems plans to treat other adult aging-related diseases with no previous cure such as Sarcopenia, Atherosclerosis, Chronic Kidney Disease (CKD)… and even aging itself with gene therapies.

“This technology could halt many of the big age associated killers in industrialized countries’” states Kekich. “Compassionate care helps patients with no other option to get access to experimental therapies that may benefit both themselves and society as a whole.”

MaxLife also seeks grants and donations for human gene therapy studies for atherosclerosis, sarcopenia and chronic kidney disease as well as for human aging. The protocols have already been developed. Please Click Here and scroll to the bottom of the page to see how to donate.

To apply for a free therapy or for more information, see http://www.maxlife.org/alzheimers-disease/ and https://maxlife.org/how-to-register-and-qualify-for-the-alzheimers-human-study/.

For Further Information, Contact: David Kekich, CEO Maximum Life Foundation.
Maximum Life Foundation is a 501(c)(3) Not-For-Profit corporation founded in 1999.
Tax I.D. #31-1656405. David A. Kekich Tel. #949-706-2468. Info@MaxLife.org

Read the full story at https://www.prweb.com/releases/first_alzheimers_disease_gene_therapy_human_study_provided_by_maximum_life_foundation_offers_10_free_therapies_for_qualifying_patients/prweb16809113.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Personalized Stem Cells, Inc. Announces First Patients Treated in FDA Approved Clinical Trial for Treatment of Osteoarthritis with Stem Cells
2. Burlington Medical Develops the First-of-Its-Kind Radiation Protection Garment Exclusively for Women
3. The first International Sigma Anti-Bonding Calcium Symposium (ISACS 2019) by CBHI
4. Personalized Stem Cells, Inc. Announces First Patients Enrolled in FDA Approved Clinical Trial for Treatment of Osteoarthritis with Stem Cells
5. Deep Science Ventures Launches Europe’s First Venture-Building Programme for Food & Agriculture
6. VetStem Biopharma Secures FDA Approval of First Human IND for its Subsidiary, Personalized Stem Cells, Inc.
7. Landsec and Spartan Bioscience Trial the World’s First On-Site Legionella DNA Test in the UK
8. Swiss Biotech Gnubiotics, Announces Global Launch of GNU100 the First Microbiome Specialty Ingredient for Companion Animal Gut Health
9. McLeod Cancer Center First in the State of South Carolina to Achieve International Radiosurgery Certification
10. Draper Hosts First MassMEDIC Women in MedTech Networking and Leadership Forum Event of 2019
11. SpineFrontier's® First SacroFUSE® and NanoFUSE Case Performed in Latin America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2020)... ... September 03, 2020 , ... ... that an extensive third-party assessment of the company’s security practices has been completed. ... federal security regulations. The comprehensive evaluation reviewed Litmus’ processes and systems, assessing them ...
(Date:8/23/2020)... ... August 21, 2020 , ... ... has been published and is now available on the company’s global website. ... the X-ray analysis community, presenting current news and crystallographic research. , The ...
(Date:8/12/2020)... ... August 11, 2020 , ... Both Roche, based ... entered into license agreements with Housey Pharma’s HMI subsidiary to gain access to ... have annual Research and Development spending in excess of US $10 billion. , ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... (PRWEB) , ... July 17, 2020 , ... ... global consulting firm for the life sciences and food industries, is pleased to ... Director of Clinical Research – Business Development. , Charles is an accomplished and ...
(Date:7/10/2020)... ... July 09, 2020 , ... In ... commonly used to suppress pigment formation in zebrafish embryos, maintaining optical transparency to ... by Dr MA has been using the zebrafish model to investigate the causes ...
(Date:7/7/2020)... ... 2020 , ... Bio-IT World has announced the winners of ... University of Chicago, Massachusetts General Hospital, Mission: Cure, and the Pistoia Alliance were ... outstanding examples of how technology innovations and strategic initiatives can be powerful forces ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... the launch of a new clinical diagnostics immuno-oncology service, TissueInsight . ... (TME). , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and ...
Breaking Biology Technology: